Dentons advised Sabadell Asabys and Thuja on the €14 million Series A financing of Gradient Denervation Technologies.
Sabadell Asabys led this round through its new fund Sadabell Asabys II, accompanied by Thuja Capital, and founding investor Sofinnova Partners.
Created in 2020, Gradient Denervation Technologies is a Paris-based medical device company that is developing an innovative catheter-based solution for the treatment of pulmonary hypertension. The new funds will enable the company to advance the clinical development of its unique, minimally invasive ultrasound-based catheter for the treatment of pulmonary hypertension, with a focus on the Group 2 population, or heart failure accompanied by high pulmonary vascular resistance.
Dentons’ Paris office advised Sabadell Asabys and Thuja with a multi-practice team, including:
On corporate matters: Partner Guillaume Kessler, assisted by counsel Laura Godard and associate Imane Sayah
On IP matters: Partner Loïc Lemercier, assisted by associates Tom Blanchet and Chen Gu
On tax and regulatory matters: Partner Julien Le Guyader, assisted by counsel Jessica Garestier (Life Sciences) and David Levy (Tax)
On commercial law aspects: Partner Emmanuelle van den Broucke, assisted by associate Margaux Serra
On employment law aspects: Partner Katell Déniel-Allioux, assisted by associate Ashley Pacquetet
